Known targets — ChEMBL curated mechanism
ABL1BCRBLKEPHA2FGRFRKFYNHCKKITLCKLYNPDGFRBSRCSRMSYES1
The experimentally established mechanism targets of Dasatinib Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 10/20 | 0.91 |
| ▸ | SRC known ✓ | P12931 | 5/20 | 0.91 |
| ▸ | LCK known ✓ | P06239 | 4/20 | 0.91 |
| ▸ | FYN known ✓ | P06241 | 2/20 | 0.91 |
| ▸ | YES1 known ✓ | P07947 | 2/20 | 0.91 |
| ▸ | LYN known ✓ | P07948 | 2/20 | 0.91 |
| ▸ | HCK known ✓ | P08631 | 2/20 | 0.91 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.91 |
| ▸ | BCR known ✓ | P11274 | 2/20 | 0.91 |
| ▸ | EPHA2 known ✓ | P29317 | 2/20 | 0.91 |
| ▸ | FRK known ✓ | P42685 | 2/20 | 0.91 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.90 |
| ▸ | FGR known ✓ | P09769 | 1/20 | 0.90 |
| ▸ | BLK known ✓ | P51451 | 1/20 | 0.90 |
| ▸ | SRMS known ✓ | Q9H3Y6 | 1/20 | 0.90 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.91 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.91 |
| ▸ | EGFR | P00533 | 2/20 | 0.91 |
| ▸ | CSF1R | P07333 | 2/20 | 0.91 |
| ▸ | RET | P07949 | 2/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dasatinib Anhydrous SCHEMBL28350326 | 0.96 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL29381185 | 0.96 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL8226 | 0.96 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL13804155 | 0.95 | ABL1 (0.82) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL16618598 | 0.95 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL28432270 | 0.95 | ABL1 (0.98) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL28828268 | 0.95 | ABL1 (0.98) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL29482416 | 0.95 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL20857008 | 0.95 | ABL1 (0.98) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL1705152 | 0.95 | ABL1 (0.98) | ABL1SRCLCKPKMYT1EPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130095100-A1 | HETEROCYCLIC KINASE INHIBITORS | CONCERT PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-8338425-B2 | Heterocyclic kinase inhibitors | CONCERT PHARMACEUTICALS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338425-B2 | Heterocyclic kinase inhibitors | CONCERT PHARMACEUTICALS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090149399-A1 | HETEROCYCLIC KINASE INHIBITORS | CONCERT PHARMACEUTICALS INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149399-A1 | HETEROCYCLIC KINASE INHIBITORS | CONCERT PHARMACEUTICALS INC. (US) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149399-A1 | HETEROCYCLIC KINASE INHIBITORS | ABL1, ABL2, SRC | ABL1 1/4885SRC 3/4885LCK 6/4885 |
| US-20130095100-A1 | HETEROCYCLIC KINASE INHIBITORS | ABL1, ABL2, SRC | ABL1 1/4885SRC 3/4885LCK 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.